OTLK · Outlook Therapeutics, Inc.
$0.59
+0.02 (+3.13%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because our cash and cash equivalents, together with $51.1 million of net proceeds from our August 2026 Offering, will not be adequate to fund our currently planned operations through at least the 12 months from the date of this Quarterly Report, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
Market Cap
$155.68M
Shares
243.45M
Volume · Oct 2
5.62M
Avg daily vol (3M)
13.63M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.59
Open$0.59
Day$0.57–0.61
52W close$0.20–2.47
Avg vol 30d5.9M
Short int32.2M · 13.2% float · 7.7d
Short vol63%
Last earningsAug 14, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 18
Up next
Next earnings call
Aug 16, 2027
Est · unconfirmed
· in 45 wks
filed Aug 18, 2026
call held Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-44.6%
Trailing year
Short interest
13.2%
Latest settlement · 7.7 days to cover
AI Brief
Q3 FY26 earnings call · Aug 14, 2026
Q3 FY26
TL;DR. Outlook Therapeutics reported its first FDA approval (LYTENAVA for wet AMD) three weeks before the call, is preparing for a U.S. launch before end of calendar 2026 with peak U.S. sales potential above $500M by 2030, and guided to $50–75M in total net revenue over the first 12 months post-launch while quarterly SG&A is expected to roughly double by year-end 2026.
Bullish
- + Cash position bolstered by $51.1M net proceeds public offering completed after quarter end.
- + Quarterly adjusted net loss narrowed to $10.9M (–$0.09/share) from $15.8M (–$0.44/share) year-over-year.
- + European unit sales rose 46% sequentially and Q4 unit sales are tracking current levels.
Bearish
- − First-year U.S. revenue expected to be back-end loaded, with only ~10% in the first three months and ~50% in the fourth quarter post-launch.
- − Forecast assumes repackaged bevacizumab remains in market and full biosimilar/TKI/IL-6/gene-therapy entry on time, limiting upside assumptions.
- − Europe performance described as 'lack of progress' with cost reset and pricing pressure requiring strategic rethink.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−23%
below
RSI (14)
37
neutral
MACD trend
Positive
52-week position
17%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−9%
trailing
6-month return
+133%
trailing
YTD return
−62%
this year
Relative strength
+121%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Flat
1 of 69 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$2.6M over 90 days · 0% sells
Short interest
Falling
13.24% of float · ▼ -2.1% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — mid 3-yr range
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+164%
Y/Y
Gross margin
1%
EPS growth
+56%
Y/Y
Free cash flow
$-52.3M
Balance sheet
$1.1B
net debt
Quant / Vol
risk profile
Volatility
152%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
9.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 14, 2026
first 12 months following the U.S. launch of LYTENAVA
Europe share of first-year net revenues
10% – 15%
first three months following launch
Percent of first-year net revenues generated during the first th
10%
by 2030
U.S. sales
$500M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−23%
Bearish
RSI (14)
37
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Flat
1 of 69 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$2.6M over 90 days · 0% sells
Short interest
Falling
13.24% of float · ▼ -2.1% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 17%
Range high $2
vs 200-day avg -20%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss attributable to common stockholders per share of common stock - basic non-GAAP | -$0.42 | Nine months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OTLK
this stock
Outlook Therapeutics, Inc.
|
$155.68M | -62.5% | +163.8% | — | 13.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OTLK | -7.3% | -8.6% | +133.5% | +3.4% | -62.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -7.1% | -8.2% | +121.3% | +2.5% | -75.3% |
Key facts
CIK
1649989
CUSIP
69012T305
13F (30d)
11 filings
3 filers
Visit website
Investor relations